INNATE PHARMA (EPA:IPH) Bristol-Myers Squibb France and Innate Pharma to host a roundtable event including internationally renowned panel speakers to discuss the topic «Innate immunity: from revolutionary discovery to revolution in therapy.»

Transparency directive : regulatory news

16/04/2012 07:15

World Leading Innate Immunity Specialists to Convene for Roundtable
Discussion:

   "Innate immunity: from revolutionary discovery to revolution in therapy" -
                       May 15, 2012, in Paris at 10:30 am

* Panel of internationally renowned speakers including Nobel Prize winners in
  Medicine 2011 and Philippe Kourilsky, professor at the Collège de France, as
  moderator;

* Dedicated website www.immunite-innee.com to submit questions that will feed
  the debate and to watch the roundtable broadcast on the following Monday.

Paris and Marseille, April 16, 2012: Bristol-Myers Squibb France and Innate
Pharma to host a roundtable event including internationally renowned panel
speakers to discuss the topic "Innate immunity: from revolutionary discovery
to revolution in therapy." Special guests, Bruce Beutler and Jules Hoffman, the
2011 Nobel Prize winners in Medicine, will join the debate which will take
place on May 15, 2012 at the Oceanographic Institute of Paris, France.

Immunotherapy, especially in cancer research, is a topical issue and source of
debate amongst the medical community. This roundtable will give an insight yet
unexplored into the innate compartment of the immune system.

Participation in this roundtable is by invitation only. A dedicated website is
now live (www.immunite-innee.com) so visitors can access detailed information
on the event and submit questions directly to the roundtable moderator Philippe
Kourilsky prior to the debate on May 15 which will fuel discussions. A video
replay will be available online shortly after the event. Discussions will be
conducted in English.

All aspects of innate immunity - from the fundamentals to clinical trials -
will be covered by our expert speakers:

- Two 2011 Nobel prize winners in medicine, Dr. Jules Hoffmann from the
Institute of Molecular and Cellular Biology at the University of Strasbourg,
and Dr. Bruce Beutler of the Center for the Genetics of Host Defense at the
University of Texas Southwestern Medical School, whose scientific discoveries
have contributed to the elucidation of mechanisms of activation of the innate
immune system;

- Pr. Jean-Yves Blay, Professor of Medical Oncology, Centre Leon Berard in
Lyon, chairing the  European organization for the research of cancer treatments
(EORTC), who has developed a wealth of experience in cancer immunotherapy;

- Dr. Nils Lonberg, Senior Vice President in charge of research and development
of biological drugs, Bristol-Myers Squibb, who participated in the development
of the first antibody modulator of T cells;

- Pr. Eric Vivier, Director, Center for Immunology Marseille-Luminy, who is a
co-founder of Innate Pharma and a specialist of natural killer cells.

Pr. Philippe Kourilsky, Chair of Immunology at the College de France and former
Director of the Pasteur Institute, will moderate the discussion.

This roundtable is organized by Bristol-Myers Squibb France and Innate Pharma:

Bristol-Myers Squibb is a biopharmaceutical company with renowned expertise in
immunology. It has developed and made available to patients a treatment for
rheumatoid arthritis, the first immunotherapy for metastatic melanoma, as well
as a treatment for the prevention of renal transplant rejection. Phase III
clinical trials are also ongoing for two immunotherapeutics in lung, prostate
and kidney cancer.

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases. Its drug candidates
belong to a new class of therapeutic agents and consist of monoclonal
antibodies aimed at immune regulatory checkpoints with a unique focus on the
innate immunity compartment. This innovative approach has been validated by two
major biopharmaceutical partners: Bristol-Myers Squibb in cancer and Novo
Nordisk A/S in inflammation.

Bristol Myers Squibb and Innate Pharma have been collaborating in the field of
innate immunomodulation since July 2011 through the IPH21 programme. Developed
by Innate Pharma and licensed by Bristol Myers Squibb, IPH2102 I s currently in
Phase I clinical trials and is the first immunotherapy specifically targeting
innate immunity cells - Natural Killer Cells - with the aim of harnessing them
to fight against cancer.

Hervé Brailly, CEO of Innate Pharma, said: "In this unique roundtable, Innate
Pharma and Bristol-Myers Squibb wish to further highlight the important
therapeutic potential of innate immunity and celebrate a field of science that
was awarded the prestigious Nobel Prize in Medicine in 2011. We very much hope
that the roundtable will broaden our understanding of this cutting-edgefield
andfoster debate amongst our peers, our stakeholders and the medical community
to help further understand the possibilities of developing highly innovative
products that modulate innate immunity."

Mike Seeley, President of Bristol-Myers Squibb France, said: "Bristol-Myers
Squibb is a global leader in thefield of immunotherapy but it is only recently
that it approached the modulation of innate immunity, through the collaboration
with Innate Pharma on the "anti-KIR" IPH21 programme. This partnership is also
reflected through our desire to instigate such meetings that we hope are
productive in terms of exchanges between academics, cancer specialists and the
industry."

About the speakers:

MODERATOR: PHILIPPE KOURILSKY

A biologist from the Ecole Polytechnique, Philippe Kourilsky has been the Chair
of Immunology at the College de France and member of the Academy of Sciences
since 1998. He has also chaired the Singapore Immunology Network (SIgN)
focusing on human immunology since its inception in 2006.

Philippe Kourilsky is a member of the Board of Directors of Veolia
Environnement, where he chairs the committee on Strategic Research Innovation
and Sustainable Development.

BRUCE BEUTLER

An American geneticist specializing in immunology, Bruce Beutler won the 2011
Nobel Prize for Medicine for his discoveries in the field of activation of the
innate immune system.

Having worked at the Rockefeller University in New York and at the University
of Texas Southwestern Medical School at Dallas, he joined, in 2000, the Scripps
Research Institute in La Jolla, California, where he taught genetics and
immunology and was head of the genetics department. He is now an adjunct
professor at that institute. Bruce Beutler currently heads the Center for the
Genetics of Host Defense, University of Texas Southwestern Medical School at
Dallas.

JEAN-YVES BLAY

Professor of Medical Oncology at the University of Lyon, Jean-Yves Blay is Head
of the Oncology Translational research center at the Centre for the Fight
Against Cancer (CLCC) Leon Berard in Lyon.

Jean-Yves Blay is also President of the European Organization for Research and
Treatment of Cancer (EORTC) and the Site Director of Integrated Research on
Cancer in Lyon (SIRIC), one of the two French sites for integrated
multidisciplinary research accredited by the Institute national du Cancer
(INCA).

JULES HOFFMANN

A French biologist from Luxembourg, Jules Hoffmann was awarded the 2011 Nobel
Prize for Medicine for his work on the immune system. In the 70s he established
the laboratory "Immune response and development in insects" at the Institute of
Molecular and Cellular Biology of the CNRS in Strasbourg, where he was director
from 1994 to 2006. Research Director at the CNRS, Jules Hoffmann was awarded
the gold medal of the CNRS.
A member of the Academy of Sciences (which he chaired in 2007 and 2008), Jules
Hoffmann was elected to the Académie française in 2012.

NILS LONBERG

Vice President in charge of research and development of biological drugs from
Bristol-Myers Squibb, Nils Lonberg was previously with Medarex and GenPharm
International. His laboratory developed and exploited a transgenic mouse
platform behind the first fully human antibodies. More than two dozen drugs
from this platform have entered clinical development, five of which are
marketed today.

ÉRIC VIVIER

Professor of Immunology at the Medical Faculty of Marseille and Hospital
Practitioner, Eric Vivier is Director of the Centre of Immunology of
Marseille-Luminy, where his team studies the cell biology of "Natural Killer"
cells. Eric Vivier is a member of the Institut Universitaire de France, member
of the scientific committee of the LNCC (French National League against Cancer),
scientific advisor for the Institute of Hematology-Immunology-Pulmonology
(INSERM) and member of the expert committee for the European Research
Council (ERC) Starting Grant. He is one of the scientific founders of Innate
Pharma.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose goal is to
discover, develop and deliver innovative drugs that help patients prevail over
serious diseases. For more information, please visit  www.bmsfrance.fr or
follow us on Twitter at http://twitter.com/#!/bmsnews.

About Innate Pharma

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases. The Company
specializes in the development of new monoclonal antibodies targeting receptors
and pathways controlling the activation of innate immunity cells. The
mechanisms controlling these cells were described at the end of the 90s,
notably by the teams of the scientists who founded Innate Pharma. This
innovating approach has been validated by two major biopharmaceutical partners:
Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation. Learn more
about Innate Pharma at www.innate-pharma.com.

Contacts

ATCG Press                            Innate Pharma
Marielle Bricman                      Laure-Hélène Mercier
Director                              Director, Investor Relations

Mob.: +33 (0)6 26 94 18 53            Phone: +33 (0)4 30 30 30 87
mb@atcg-partners.com                  Laure-Helene.Mercier@innate-pharma.fr

Bristol-Myers Squibb France
Catherine Liabeuf
Associated Director Public
Affairs

Phone: +33 (0)1 58 83 87 92
catherine.liabeuf@bms.com

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Bristol-Myers Squibb France and Innate Pharma to host a roundtable event including internationally renowned panel speakers to discuss the topic «Innate immunity: from revolutionary discovery to revolution in therapy.»

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories